Navigation Links
APPLIED INTEGRIN SCIENCES, INC. LAUNCHES CROWDFUNDING CAMPAIGN TO RAISE FUNDS FOR ITS CANCER DRUG DEVELOPMENT PROGRAM
Date:9/25/2013

LOS ANGELES, Sept. 25, 2013 /PRNewswire-iReach/ -- Applied Integrin Sciences, Inc. announced today it launched its first crowdfunding campaign to raise funding to accelerate the development of its cancer-fighting drug that is planned to boost the survival and quality of life for patients with ovarian cancer, breast cancer, prostate cancer, and other cancers, an initiative facilitated by the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California; Three Two One Productions; When You Wish; and the women who share their ovarian cancer experiences: Diem Brown, Entertainment reporter and former contestant on MTV's Real World/Road Rules Challenge, who shares her experience of being diagnosed with ovarian cancer at age 23 (The MEDGift Foundation);  Amy Cohen Epstein who watched her mother, Lynne Cohen, suffer and succumb from ovarian cancer (Lynne Cohen Foundation); Paulinda Schimmel Babbini who saw her daughter, Robin, diagnosed with ovarian cancer at age 17 and  lose her life at age 20 (The Ovarian Cancer Circle); and, Diane Balma, former executive at the Susan G. Komen For the Cure, explains the importance of involving the general public in supporting medical research for cancer.

Through the miracle of the internet and social media the public now has the opportunity to directly fund cutting-edge cancer research and drug development.  To donate to the company's drug development program simply click on the following WhenYouWish link:            http://www.whenyouwish.com/project/boostcancersurvivalrates

1 minute of your time and a donation of your choosing will make a difference.

Applied Integrin Sciences, Inc. scientists' at the University of Southern California Keck School of Medicine and the USC Norris Comprehensive Cancer Center discovered a novel cancer-fighting therapeutic drug has demonstrated effective reduction of tumor growth and progression on six aggressive tumors: triple negative breast cancer, ovarian cancer, primary prostate cancer, prostate bone metastasis, melanoma, and brain cancer – glioblastoma.   The company identified a new approach to treating ovarian cancer using its first cancer drug candidate that was funded by the National Cancer Institute of the National Institutes of Health, and is beginning the final research steps required by the FDA prior to submitting its application to conduct human clinical trials. 

The company's goal is to complete clinical drug development and achieve the same results as obtained in the laboratory.  If achieved this novel cancer treatment could change the current standard of care and improve patient survival and quality of life. And if demonstrated safe in early clinical trials, the company also intends to embark on clinical development for other cancer indications including breast and prostate cancers.

About Applied Integrin Sciences

Applied Integrin Sciences is a pre-clinical stage biopharmaceutical company committed to discover, develop, and commercialize novel protein drug therapies for cancer treatments that reduce solid tumor growth and progression and improve patient survival and quality of life.  The Company's Founding Scientists discovered, developed and patented a drug discovery platform to produce novel integrin modulating recombinant protein therapeutics that reduce tumor growth and progression in primary tumors, newly growing tumor-induced vasculature, and metastatic foci. The company is currently evaluating a novel treatment for ovarian cancer, an orphan indication recently funded by the NIH, as its first indication. For additional information about the company, please visit www.integrins.com.

About the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California

The Alfred E. Mann Institute for Biomedical Engineering was established at the University of Southern California in 1998.  Its mission is to help bridge the gap between biomedical innovation and the creation of commercially-successful medical products to improve and save lives.

About Three Two One Productions

Three Two One Productions is a company led by seasoned storytellers from film and television who create cutting edge business, bios, and legacy videos.

About When You Wish

When You Wish is a leading Internet "crowdfunding" company that combines payment processing and publishing tools to help entrepreneurs raise money online for their ideas or causes.

Source: Applied Integrin Sciences, Inc.

Public Relations.

(805) 715-4166

Media Contact: Public Relations, Applied Integrin Sciences, Inc., (805) 715-4166, info@integrins.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Applied Integrin Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
4. KannaLife Sciences, Inc. Signs Exclusive License Agreement with National Institutes of Health Office of Technology Transfer (NIH-OTT)
5. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
6. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
7. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
8. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
9. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
10. QPS Acquires JSW Life Sciences, Largest Independent Contract Research Organization in Austria
11. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):